Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

rafarm s.a. - iloprost - soluciÓn para inhalaciÓn por nebulizador - 10 microgramos - iloprost 10 microgramos - iloprost

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - valsartan; amlodipino besilato; hidroclorotiazida - comprimido recubierto con pelÍcula - 160 mg/10 mg/12,5 mg - valsartan 160 mg; amlodipino besilato 10 mg; hidroclorotiazida 12,5 mg - valsartán, amlodipino e hidroclorotiazida

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - valsartan; amlodipino besilato; hidroclorotiazida - comprimido recubierto con pelÍcula - 160 mg/5 mg/12,5 mg - valsartan 160 mg; amlodipino besilato 5 mg; hidroclorotiazida 12,5 mg - valsartán, amlodipino e hidroclorotiazida

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios cinfa s.a. - valsartan; amlodipino besilato; hidroclorotiazida - comprimido recubierto con pelÍcula - 160 mg/5 mg/12,5 mg - valsartan 160 mg; amlodipino besilato 5 mg; hidroclorotiazida 12,5 mg - valsartán, amlodipino e hidroclorotiazida

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vianex s.a. - capreomicina sulfato - polvo para soluciÓn inyectable - 1.000 mg - capreomicina sulfato 1000 mg - capreomicina

Soome - hispaania - Ecolab

ecolab deutschland gmbh -

Euroopa Liit - hispaania - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibrosis quística - otros productos del sistema respiratorio - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Euroopa Liit - hispaania - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinoma, pulmón no microcítico - otros agentes antineoplásicos, inhibidores de la proteína quinasa - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Euroopa Liit - hispaania - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocítica, crónica, b-cell - agentes antineoplásicos - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Euroopa Liit - hispaania - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - fibrosis quística - otros productos del sistema respiratorio - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.